Forte Biosciences (FBRX) Total Debt (2016 - 2019)
Forte Biosciences (FBRX) posted quarterly Total Debt of $22.1 million for Q2 2019, down 14.8% year-over-year from $25.9 million in Q2 2018, and down 8.53% quarter-over-quarter from $24.1 million in Q1 2019.
Forte Biosciences (FBRX) Total Debt (2016 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported Total Debt for 4 consecutive years, with $22.1 million the latest figure, recorded in Q2 2019.
- In Q2 2019, Total Debt fell 14.8% year-over-year to $22.1 million; the TTM figure through Jun 2019 stood at $22.1 million (down 14.8% YoY), while the FY2018 annual figure was $26.2 million, up 622.79% from the prior year.
- Total Debt fell to $22.1 million in Q2 2019 per FBRX's latest filing, from $24.1 million in the prior quarter.
- Across five years, Total Debt topped out at $26.2 million in Q4 2018 and bottomed at $2.0 million in Q1 2018.
- Historically, Total Debt has averaged $14.6 million across 4 years, with a median of $10.2 million in 2016.
- Annual changes were most pronounced in 2018 — Total Debt slumped 77.02% — and 2019, when it surged 1124.09%.
- Forte Biosciences' Total Debt stood at $10.2 million in 2016, then sank by 64.6% to $3.6 million in 2017, then jumped by 622.79% to $26.2 million in 2018, then fell by 15.73% to $22.1 million in 2019.
- Business Quant data shows FBRX's Total Debt at $22.1 million in Q2 2019, $24.1 million in Q1 2019, and $26.2 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 22.08 Mn |
| Mar 31, 2019 | 24.14 Mn |
| Dec 31, 2018 | 26.20 Mn |
| Sep 30, 2018 | 26.06 Mn |
| Jun 30, 2018 | 25.91 Mn |
| Mar 31, 2018 | 1.97 Mn |
| Dec 31, 2017 | 3.63 Mn |
| Sep 30, 2017 | 5.28 Mn |
| Jun 30, 2017 | 6.93 Mn |
| Mar 31, 2017 | 8.58 Mn |
| Dec 31, 2016 | 10.24 Mn |